Please assess the completion status of the following clinical trial:

Trial Title: Prevention of Acute Exacerbation in Subjects With COPD by Bacterial Decolonization in Lower Respiratory Tract

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Written informed consent must be obtained before any assessment is performed~2. Male or female adults aged 18-65 years~3. Diagnosed with COPD according to GOLD 2016 (The ratio of post-bronchodilator forced expiratory volume in 1 second (FEV1) to force vital capacity (FVC)\<0.70 with the use of salbutamol 400ug)~4. Moderate to very severe airflow limitation (post-bronchodilator FEV1 \< 80% of the predicted normal value)~5. A documented history of at least 2 COPD exacerbation in the previous 12 months that required treatment with systemic glucocorticoids and/or antibiotics, or at least 1 exacerbation in the previous 12 months that requires hospitalization.~6. In the stable stage of COPD~Exclusion Criteria:~1. Patients who have clinically significant and chronic hepatic, renal, cardiovascular and gastrointestinal abnormalities or malignant tumor (except for lung cancer) which could interfere with the assessment of the efficacy and safety of the study treatment~2. Patients who are in critical conditions~3. Patients who have had a COPD exacerbation that required treatment with antibiotics and/or systemic corticosteroids or an acute exacerbation of any other diseases in the 4 weeks prior to screening~4. Patients with concomitant pulmonary disease (including but not limited to bronchiectasis, interstitial lung disease, asthma)~5. Patients who are highly likely to be lost during the 3-month treatment and the 1-year follow up~6. Pregnant or nursing (lactating) women~7. Patients who have been vaccinated against influenza in the current year, or against Streptococcus pneumoniae within five years, or have vaccination contraindications~8. Patients who are allergic to amikacin or other aminoglycosides~9. Patients who have participated in any interventional clinical trials in the three months prior to screening~10. Patients with mental diseases or cognitive disorders which could interfere with treatment and follow-up

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- oral probiotics (Type: EXPERIMENTAL): None
- aerosol inhaled amikacin (Type: EXPERIMENTAL): None
- combined vaccination (Type: EXPERIMENTAL): None
- conventional therapy (blank control) (Type: NO_INTERVENTION): According to the subjects' personal characteristics and guidance of The Global Initiative for Chronic Obstructive Lung Disease(GOLD) 2017, the doctor in charge prescribes appropriate medication, including but not limited to bronchodilators, inhaled glucocorticoids and long term oxygen therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).